Scarica l'app Stockscreener
15.54
0.91%
0.14
Dopo l'orario di chiusura:
15.54
Precedente Chiudi:
$15.40
Aprire:
$15.5
Volume 24 ore:
490.84K
Relative Volume:
0.82
Capitalizzazione di mercato:
$922.26M
Reddito:
-
Utile/perdita netta:
$-85.21M
Rapporto P/E:
-8.2222
EPS:
-1.89
Flusso di cassa netto:
$-68.53M
1 W Prestazione:
-4.66%
1M Prestazione:
-24.42%
6M Prestazione:
-24.71%
1 anno Prestazione:
-34.98%
Intervallo 1D:
$15.06
$15.79
Intervallo di 1 settimana:
$15.06
$16.39
Portata 52W:
$13.30
$25.37
Enliven Therapeutics Inc Stock (ELVN) Company Profile
Nome
Enliven Therapeutics Inc
Settore
Industria
Telefono
720-647-8519
Indirizzo
6200 LOOKOUT ROAD, BOULDER
Confronta ELVN con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ELVN
Enliven Therapeutics Inc
|
15.54 | 913.95M | 0 | -85.21M | -68.53M | -1.89 |
|
VRTX
Vertex Pharmaceuticals Inc
|
452.13 | 115.03B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
776.31 | 81.12B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
400.17 | 52.54B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
839.99 | 51.78B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
177.12 | 37.12B | 447.02M | -1.18B | -906.14M | -6.1812 |
Enliven Therapeutics Inc Stock (ELVN) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-06-16 | Iniziato | Goldman | Buy |
| 2024-12-13 | Iniziato | BTIG Research | Buy |
| 2024-09-09 | Iniziato | H.C. Wainwright | Buy |
| 2024-06-11 | Iniziato | Robert W. Baird | Outperform |
| 2024-04-09 | Iniziato | Mizuho | Buy |
| 2023-03-29 | Iniziato | Jefferies | Buy |
Mostra tutto
Enliven Therapeutics Inc Borsa (ELVN) Ultime notizie
Enliven Therapeutics, Inc. (NASDAQ:ELVN) Receives Average Rating of "Moderate Buy" from Brokerages - MarketBeat
Avoiding Lag: Real-Time Signals in (ELVN) Movement - Stock Traders Daily
Enliven Therapeutics CSO sells $84k in shares By Investing.com - Investing.com Nigeria
Enliven Therapeutics (NASDAQ:ELVN) Insider Joseph Lyssikatos Sells 5,000 Shares of Stock - MarketBeat
Enliven Therapeutics CSO sells $84k in shares - Investing.com
Enliven Therapeutics (NASDAQ:ELVN) Stock Price Down 6.1%Here's What Happened - MarketBeat
First Week of February 2026 Options Trading For Enliven Therapeutics (ELVN) - Nasdaq
Portfolio Shifts: Is Enliven Therapeutics Inc. stock near bottom after decline2025 Volatility Report & Daily Entry Point Trade Alerts - moha.gov.vn
Will Enliven Therapeutics Inc. stock benefit from AI adoption2025 Top Decliners & Fast Exit/Entry Strategy Plans - Улправда
Is Enliven Therapeutics Inc. stock near bottom after declineFed Meeting & Free Weekly Watchlist of Top Performers - Улправда
Technical Reactions to ELVN Trends in Macro Strategies - Stock Traders Daily
What risks investors should watch in Enliven Therapeutics Inc. stockJuly 2025 Technicals & Weekly Chart Analysis and Trade Guides - DonanımHaber
Is Enliven Therapeutics Inc. stock a buy before product launchesJuly 2025 Volume & Verified Stock Trade Ideas - DonanımHaber
How Enliven Therapeutics Inc. stock reacts to oil prices2025 Top Gainers & Long-Term Investment Growth Plans - DonanımHaber
How resilient is Enliven Therapeutics Inc. stock in market downturnsWeekly Trend Report & Low Volatility Stock Suggestions - DonanımHaber
Enliven Therapeutics Earnings Notes - Trefis
Will Enliven Therapeutics Inc. stock gain from strong economy2025 Biggest Moves & Real-Time Buy Zone Alerts - Улправда
Enliven Therapeutics (ELVN) Stock Analysis Report | Financials & Insights - Benzinga
Enliven Therapeutics (NASDAQ: ELVN) registers shares for 2025 equity inducement plan - Stock Titan
Enliven Therapeutics, Inc.Common Stock (NQ: ELVN - Markets Financial Content
VIX Spike: How resilient is Enliven Therapeutics Inc stock in market downturnsQuarterly Trade Report & Risk Managed Investment Signals - moha.gov.vn
5AM Venture Management LLC Reduces Stock Holdings in Enliven Therapeutics, Inc. $ELVN - Defense World
CEO moves at Prolynx, Centessa, Kyowa Kirin, Enliven, Expression - biocentury.com
Enliven Therapeutics (ELVN) officer-director discloses no owned securities - Stock Titan
Enliven Therapeutics (NASDAQ:ELVN) COO Anish Patel Sells 6,663 Shares of Stock - MarketBeat
Enliven Therapeutics Reports Inducement Grants as Permitted by the Nasdaq Listing Rules - Nasdaq
Enliven Therapeutics (NASDAQ:ELVN) Shares Down 6.5% Following Insider Selling - MarketBeat
Enliven Therapeutics appoints Rick Fair as new CEO - Investing.com
Enliven Therapeutics, Inc. Announces Management Changes - marketscreener.com
Enliven Therapeutics appoints Rick Fair as new CEO, shares down - TradingView — Track All Markets
Enliven Therapeutics Appoints Rick Fair as CEO - marketscreener.com
Enliven Therapeutics appoints Rick Fair as new CEO By Investing.com - Investing.com South Africa
Enliven Therapeutics Appoints New CEO and Director - TradingView — Track All Markets
[8-K] Enliven Therapeutics, Inc. Reports Material Event | ELVN SEC FilingForm 8-K - Stock Titan
Enliven Therapeutics announces new CEO to drive next phase of development - marketscreener.com
Enliven Therapeutics Announces New CEO to Drive Next Phase of Development - PR Newswire
COO Patel Sells 6,663 ($140.1K) Of Enliven Therapeutics Inc [ELVN] - TradingView — Track All Markets
Top investors say Enliven Therapeutics Inc (ELVN) ticks everything they need - setenews.com
Enliven Therapeutics (NASDAQ:ELVN) Sees Unusually-High Trading VolumeHere's What Happened - MarketBeat
Enliven Therapeutics (ELVN): Evaluating Valuation After a Recent Share Price Rebound and Ongoing Clinical Progress - Yahoo Finance
Tiny Biotech Terns Takes Aim At Novartis' Leukemia Blockbuster - Benzinga
Enliven Therapeutics, Inc. (NASDAQ:ELVN) Receives Average Rating of “Moderate Buy” from Brokerages - Defense World
Enliven Therapeutics: ENABLE trial shows promise in treating atypical fusion CML - Traders Union
Trading the Move, Not the Narrative: (ELVN) Edition - news.stocktradersdaily.com
Will Enliven Therapeutics Inc stock benefit from AI adoptionJuly 2025 Setups & Long-Term Capital Growth Strategies - moha.gov.vn
Affinity Asset Advisors LLC Buys Shares of 400,000 Enliven Therapeutics, Inc. $ELVN - MarketBeat
Enliven Therapeutics (NASDAQ:ELVN) and PreveCeutical Medical (OTCMKTS:PRVCF) Head-To-Head Analysis - Defense World
Can Enliven Therapeutics Inc. stock deliver surprise earnings beatTrade Analysis Report & Free Low Drawdown Momentum Trade Ideas - Newser
Enliven Therapeutics (ELVN): Assessing Valuation After a Recent 13% Share Price Rebound - Sahm
Who are in the management team of Enliven Therapeutics, Inc.? - Markets Mojo
Wall Street Analysts Believe Enliven Therapeutics, Inc. (ELVN) Could Rally 101.26%: Here's is How to Trade - sharewise.com
Enliven Therapeutics Inc Azioni (ELVN) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Enliven Therapeutics Inc Azioni (ELVN) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Lyssikatos Joseph P | CHIEF SCIENTIFIC OFFICER |
Dec 19 '25 |
Sale |
16.84 |
5,000 |
84,206 |
897,688 |
| Kunkel Lori Anne | Director |
Dec 17 '25 |
Option Exercise |
1.12 |
15,958 |
17,873 |
30,712 |
0.57%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):